Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva VP-biogenerics

Executive Summary

Teva taps board member Amir Elstein for VP-biogenerics post beginning Jan. 1. The appointment could signal a significant push at Teva for the development of follow-on biologics. Elstein will step down as a board member before assuming the new post. The company announced a slew of personnel changes Nov. 30: Teva North America CEO William Fletcher will assume the role of Teva North America chairman; Teva USA CEO George Barrett will rise to the position of Teva North America CEO; Teva USA Exec VP William Marsh will fill Barrett's post...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS045078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel